ATR
Published on 05/01/2026 at 10:49 am EDT
For the Quarters Ended On
March 2026
December 2025
September 2025
June 2025
March 2025
December 2024
September 2024
June 2024
March 2024
December 2023
September 2023
June 2023
Comparative Income Statements
Net Sales
$ 982.9
$ 962.7
$ 961.1
$ 966.0
$ 887.3
$ 848.1
$ 909.3
$ 910.1
$ 915.4
$ 838.5
$ 893.0
$ 895.9
Gross Margin
$ 351.9
$ 338.2
$ 363.1
$ 367.0
$ 336.4
$ 329.4
$ 350.8
$ 342.6
$ 332.7
$ 312.3
$ 326.3
$ 322.2
Gross Margin % of Sales
36%
35%
38%
38%
38%
39%
39%
38%
36%
37%
37%
36%
Selling, general and Administrative
$ 167.6
$ 151.3
$ 148.8
$ 151.1
$ 155.3
$ 138.5
$ 141.6
$ 149.3
$ 152.8
$ 138.3
$ 138.1
$ 141.4
Selling, general and Administrative % of Sales
17%
16%
15%
16%
17%
16%
16%
16%
17%
16%
15%
16%
Depreciation and Amortization
$ 75.7
$ 76.6
$ 75.2
$ 69.9
$ 65.6
$ 67.5
$ 67.0
$ 65.0
$ 64.3
$ 64.4
$ 62.7
$ 62.3
Depreciation and Amortization % of Sales
8%
8%
8%
7%
7%
8%
7%
7%
7%
8%
7%
7%
Interest Expense
$ 16.9
$ 17.0
$ 13.5
$ 10.9
$ 11.4
$ 11.4
$ 12.3
$ 10.1
$ 10.2
$ 10.5
$ 10.0
$ 9.7
Interest Expense % of Sales
2%
2%
1%
1%
1%
1%
1%
1%
1%
1%
1%
1%
Interest Income
$ 3.6
$ 4.6
$ 2.4
$ 1.9
$ 2.8
$ 3.1
$ 3.0
$ 3.1
$ 2.9
$ 2.1
$ 0.9
$ 0.6
Interest Income % of Sales
0.4%
0.5%
0.2%
0.2%
0.3%
0.4%
0.3%
0.3%
0.3%
0.3%
0.1%
0.1%
Net Income
$ 72.7
$ 74.3
$ 127.9
$ 111.7
$ 78.8
$ 100.9
$ 100.0
$ 90.5
$ 83.1
$ 62.4
$ 84.3
$ 83.1
Financial Metrics
Core Sales Growth %
0%
5%
1%
3%
0%
2%
2%
3%
5%
2%
2%
4%
Adjusted EPS
$ 1.19
$ 1.25
$ 1.62
$ 1.66
$ 1.20
$ 1.52
$ 1.49
$ 1.37
$ 1.26
$ 1.21
$ 1.39
$ 1.23
Adjusted EBITDA
$ 188.9
$ 190.8
$ 222.6
$ 218.4
$ 183.3
$ 194.9
$ 208.4
$ 192.8
$ 178.8
$ 179.4
$ 193.4
$ 181.2
Adjusted EBITDA Margin
19.2%
19.8%
23.2%
22.6%
20.7%
23.0%
22.9%
21.2%
19.5%
21.4%
21.7%
20.2%
Effective Tax Rate
22.4%
18.9%
17.1%
20.0%
25.8%
13.1%
23.8%
23.5%
20.5%
22.8%
23.4%
25.1%
Comparative Balance Sheets
Cash, equivalents and short-term investments
$ 229.5
$ 409.5
$ 264.8
$ 169.8
$ 136.8
$ 226.2
$ 327.9
$ 223.9
$ 201.1
$ 223.6
$ 151.6
$ 121.0
Accounts and notes receivable, less ADA
$ 833.3
$ 803.8
$ 799.0
$ 800.2
$ 742.7
$ 658.1
$ 699.0
$ 737.8
$ 724.0
$ 677.8
$ 717.5
$ 718.6
Inventories
$ 551.5
$ 537.8
$ 547.3
$ 527.4
$ 483.5
$ 461.8
$ 488.5
$ 484.6
$ 496.8
$ 513.1
$ 490.9
$ 516.3
Total Current Assets
$ 1,768.3
$ 1,893.6
$ 1,783.6
$ 1,663.0
$ 1,511.8
$ 1,478.4
$ 1,665.6
$ 1,593.7
$ 1,560.0
$ 1,549.3
$ 1,502.8
$ 1,516.0
Property, Plant and Equipment, Net
$ 1,660.9
$ 1,676.5
$ 1,639.6
$ 1,584.5
$ 1,489.4
$ 1,447.2
$ 1,505.2
$ 1,466.3
$ 1,464.4
$ 1,478.1
$ 1,388.6
$ 1,395.8
Total Assets
$ 5,097.8
$ 5,252.7
$ 5,100.8
$ 4,865.4
$ 4,527.1
$ 4,432.3
$ 4,625.2
$ 4,453.3
$ 4,437.1
$ 4,451.9
$ 4,298.2
$ 4,347.7
Accounts payable, accrued and other liabilities
$ 840.9
$ 822.9
$ 844.6
$ 817.4
$ 762.6
$ 730.0
$ 773.5
$ 762.4
$ 760.8
$ 793.1
$ 740.8
$ 753.7
Total Current Liabilities
$ 1,063.0
$ 1,166.4
$ 1,499.2
$ 1,368.9
$ 1,208.0
$ 1,068.3
$ 1,026.7
$ 1,168.1
$ 1,196.1
$ 1,251.3
$ 1,231.6
$ 1,029.8
Long-Term Debt, Net
$ 1,143.4
$ 1,139.4
$ 546.0
$ 535.1
$ 561.2
$ 688.1
$ 822.7
$ 681.5
$ 680.4
$ 681.2
$ 680.1
$ 949.9
Total Liabilities
$ 2,450.2
$ 2,566.7
$ 2,313.3
$ 2,147.6
$ 1,975.6
$ 1,946.4
$ 2,071.6
$ 2,043.0
$ 2,074.2
$ 2,130.6
$ 2,084.5
$ 2,159.3
Total Stockholders' Equity
$ 2,647.6
$ 2,686.0
$ 2,787.5
$ 2,717.8
$ 2,551.5
$ 2,485.9
$ 2,553.6
$ 2,410.2
$ 2,362.9
$ 2,321.3
$ 2,213.7
$ 2,188.4
Cash Flows
Net Cash Provided by Operations
$ 118.7
$ 183.7
$ 177.6
$ 126.0
$ 82.7
$ 178.2
$ 229.3
$ 143.6
$ 92.3
$ 219.6
$ 173.4
$ 83.9
Capital Expenditures less Government Grants
$ 65.4
$ 86.8
$ 63.3
$ 60.1
$ 56.9
$ 66.1
$ 66.6
$ 68.2
$ 75.7
$ 81.1
$ 76.2
$ 77.2
Free Cash Flow
$ 53.3
$ 96.9
$ 114.3
$ 65.8
$ 25.9
$ 112.2
$ 162.7
$ 75.4
$ 16.7
$ 138.5
$ 97.2
$ 6.7
Dividends paid
$ 30.9
$ 31.5
$ 29.6
$ 29.7
$ 29.9
$ 29.9
$ 29.9
$ 27.2
$ 27.1
$ 27.0
$ 26.9
$ 24.9
Purchase of treasury stock
$ 100.0
$ 175.0
$ 40.0
$ 70.0
$ 80.0
$ 37.3
$ 14.2
$ 5.1
$ 12.1
$ 10.3
$ 8.3
$ 9.3
Aptar Pharma
Net Sales
$ 438.6
$ 440.0
$ 445.4
$ 442.6
$ 409.5
$ 400.7
$ 420.6
$ 414.5
$ 407.3
$ 385.1
$ 389.2
$ 390.7
Core Sales Growth %
-1%
4%
2%
3%
3%
4%
7%
7%
13%
11%
8%
13%
Adjusted EBITDA
$ 146.2
$ 142.6
$ 165.8
$ 156.8
$ 142.5
$ 143.1
$ 151.6
$ 141.5
$ 132.2
$ 131.1
$ 136.3
$ 125.9
Adjusted EBITDA Margin
33.3%
32.4%
37.2%
35.4%
34.8%
35.7%
36.0%
34.1%
32.5%
34.1%
35.0%
32.2%
Aptar Beauty
Net Sales
$ 363.6
$ 341.1
$ 327.8
$ 334.8
$ 305.7
$ 274.1
$ 302.9
$ 321.5
$ 327.3
$ 287.7
$ 324.0
$ 329.6
Core Sales Growth %
3%
10%
0%
1%
-3%
-3%
-6%
-1%
-1%
-6%
2%
3%
Adjusted EBITDA
$ 40.5
$ 34.8
$ 39.7
$ 47.1
$ 37.1
$ 33.9
$ 40.2
$ 44.6
$ 41.1
$ 42.3
$ 41.1
$ 43.1
Adjusted EBITDA Margin
11.1%
10.2%
12.1%
14.1%
12.1%
12.4%
13.3%
13.9%
12.6%
14.7%
12.7%
13.1%
Aptar Closures
Net Sales
$ 180.7
$ 181.6
$ 188.0
$ 188.6
$ 172.1
$ 173.3
$ 185.8
$ 174.0
$ 180.8
$ 165.7
$ 179.8
$ 175.6
Core Sales Growth %
0%
1%
-1%
7%
-2%
7%
4%
0%
1%
-4%
-9%
-8%
Adjusted EBITDA
$ 23.7
$ 27.0
$ 30.3
$ 31.9
$ 27.3
$ 27.9
$ 32.0
$ 27.1
$ 27.2
$ 22.3
$ 27.6
$ 27.8
Adjusted EBITDA Margin
13.1%
14.9%
16.1%
16.9%
15.8%
16.1%
17.2%
15.6%
15.0%
13.5%
15.4%
15.8%
This document is a compiled summary of selected financial information extracted from Aptar's prior twelve quarters of Form 10-Q filings and should be read together with the Company's full SEC filings, which contain important footnotes and context. It is provided solely for the convenience of users to facilitate period-over-period comparison. While care has been taken to ensure the information is accurate as of the dates of the original filings, this compilation does not replace or supersede the complete financial statements and disclosures contained in Aptar's SEC filings.
For comprehensive information, including footnotes and management's discussion and analysis, users should refer to the Company's full Form 10-Q and Form 10-K filings available on the SEC's website and the Company's Investor Relations page.
This document refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. Core sales exclude acquisitions and changes in foreign currency sales. Core sales growth is calculated as current sales, less acquisitions, less constant currency prior year sales, divided by constant currency prior year sales. The quarterly Adjusted EPS is not neutralized for year to year foreign currency translation effects. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. For the three and twelve months ended December 31, 2025, "Other special items" include costs incurred related to non-ordinary-
course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar's claims of trade-secret misappropriation and contractual breaches and ARS's counterclaims under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar's ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to "Legal Proceedings" within Note 12 - Commitments and Contingencies within Aptar's Form 10-K for the period ended December 31, 2025 for more information.. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar's management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management's view, do not reflect Aptar's core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar's management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.
Reconciliation of Adjusted EBIT
and Adjusted EBITDA to Net Income (Unaudited)
March
2026
December
2025
September
2025
June
2025
March
2025
December
2024
September
2024
June
2024
March
2024
December
2023
September
2023
June
2023
AptarGroup, Inc.
Net Sales $ 982.9
$ 962.7
$ 961.1
$ 966.0
$ 887.3
$ 848.1
$ 909.3
$ 910.1
$ 915.4
$ 838.5
$ 893.0
$ 895.9
Reported net income $ 72.8
$ 74.3
$ 127.8
$ 111.7
$ 78.7
$ 100.9
$ 99.9
$ 90.5
$ 82.9
$ 62.2
$ 84.3
$ 83.0
Reported income taxes $ 21.0
$ 17.3
$ 26.3
$ 28.0
$ 27.4
$ 15.2
$ 31.2
$ 27.8
$ 21.4
$ 18.4
$ 25.8
$ 27.8
Reported income before income taxes $ 93.8
$ 91.5
$ 154.1
$ 139.7
$ 106.0
$ 116.1
$ 131.1
$ 118.2
$ 104.3
$ 80.6
$ 110.0
$ 110.9
Adjustments:
Restructuring initiatives $ 1.1
$ 4.0
$ 2.2
$ 1.6
$ 2.0
$ 3.3
$ 3.9
$ 2.3
$ 3.5
$ 25.4
$ 6.2
$ 1.9
Curtailment gain related to restructuring initiatives $ -
$ (0.1)
$ -
$ -
$ -
$ -
$ (1.9)
$ -
$ -
$ -
$ -
$ -
Net investment (gain) loss $ 1.1
$ 1.3
$ 0.2
$ (2.1)
$ 1.1
$ (0.2)
$ (1.0)
$ 0.1
$ (0.6)
$ 0.4
$ 1.2
$ (2.9)
Realized gain on investments included in net $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ 4.2
$ -
Gain from remeasurement of equity method $ -
$ -
$ (26.5)
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Transaction costs related to acquisitions $ 0.0
$ 0.4
$ 0.7
$ 0.3
$ -
$ -
$ -
$ 0.1
$ -
$ 0.2
$ -
$ -
Purchase accounting adjustments related to $ 0.1
$ 0.6
$ 1.1
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Other special items $ 3.7
$ 4.0
$ 4.4
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Adjusted earnings before income taxes $ 99.9
$ 101.8
$ 136.2
$ 139.5
$ 109.2
$ 119.2
$ 132.1
$ 120.8
$ 107.2
$ 106.7
$ 121.6
$ 109.9
Interest expense $ 16.9
$ 17.0
$ 13.5
$ 10.9
$ 11.4
$ 11.4
$ 12.3
$ 10.1
$ 10.2
$ 10.5
$ 10.0
$ 9.7
Interest income $ (3.6)
$ (4.6)
$ (2.4)
$ (1.9)
$ (2.8)
$ (3.1)
$ (3.0)
$ (3.1)
$ (2.9)
$ (2.1)
$ (0.9)
$ (0.6)
Adjusted earnings before net interest and taxes (Adjusted $ 113.2
$ 114.2
$ 147.4
$ 148.5
$ 117.7
$ 127.5
$ 141.4
$ 127.8
$ 114.5
$ 115.1
$ 130.7
$ 119.0
Depreciation and amortization $ 75.7
$ 76.6
$ 75.2
$ 69.9
$ 65.6
$ 67.5
$ 67.0
$ 65.0
$ 64.3
$ 64.4
$ 62.7
$ 62.3
Adjusted EBITDA $ 188.9
$ 190.8
$ 222.6
$ 218.4
$ 183.3
$ 194.9
$ 208.4
$ 192.8
$ 178.8
$ 179.4
$ 193.4
$ 181.2
Adjusted EBITDA % 19.2%
19.8%
23.2%
22.6%
20.7%
23.0%
22.9%
21.2%
19.5%
21.4%
21.7%
20.2%
investment (gain) loss above investment
acquisitions and investments
EBIT)
Aptar Pharma
Adjustments:
Net Sales $ 438.6
$ 440.0
$ 445.4
$ 442.6
$ 409.5
$ 400.7
$ 420.6
$ 414.5
$ 407.3
$ 385.1
$ 389.2
$ 390.7
Reported net income $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Reported income taxes $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Reported income before income taxes $ 106.7
$ 102.6
$ 124.8
$ 122.6
$ 111.1
$ 111.9
$ 120.2
$ 111.8
$ 103.4
$ 99.8
$ 108.1
$ 98.1
Restructuring initiatives
$ 0.0 $
(0.1) $
0.9 $
0.1 $
0.2 $
(0.1) $
0.6 $
0.1 $
0.0 $
3.2 $
0.1 $
0.4
Curtailment gain related to restructuring initiatives $ Net investment (gain) loss $
Realized gain on investments included in net $ investment (gain) loss above
Gain from remeasurement of equity method $ investment
Transaction costs related to acquisitions $
Purchase accounting adjustments related to $ acquisitions and investments
Other special items $
- $
- $
- $
- $
0.0 $
0.1 $
3.7 $
- $
- $
- $
- $
0.4 $
0.1 $
4.0 $
- $ - $
- $ - $
- $ - $
- $ - $
0.6 $ - $
- $ - $
4.4 $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $
- $ - $ - $ -
- $ - $ - $ -
- $ - $ - $ -
- $ - $ - $ -
- $ - $ - $ -
- $ - $ - $ -
- $ - $ - $ -
Adjusted earnings before income taxes
$ 110.6
$ 106.9
$ 130.7
$ 122.7
$ 111.3
$ 111.9
$ 120.8
$ 111.9
$ 103.4
$ 103.0
$ 108.2
$ 98.5
Interest expense
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Interest income
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Adjusted earnings before net interest and taxes (Adjusted
EBIT)
$ 110.6
$ 106.9
$ 130.7
$ 122.7
$ 111.3
$ 111.9
$ 120.8
$ 111.9
$ 103.4
$ 103.0
$ 108.2
$ 98.5
Depreciation and amortization
$ 35.6
$ 35.7
$ 35.1
$ 34.2
$ 31.1
$ 31.2
$ 30.8
$ 29.6
$ 28.8
$ 28.1
$ 28.1
$ 27.3
Adjusted EBITDA
$ 146.2
$ 142.6
$ 165.8
$ 156.8
$ 142.5
$ 143.1
$ 151.6
$ 141.5
$ 132.2
$ 131.1
$ 136.3
$ 125.9
Adjusted EBITDA %
33.3%
32.4%
37.2%
35.4%
34.8%
35.7%
36.0%
34.1%
32.5%
34.1%
35.0%
32.2%
Aptar Beauty
Net Sales
$ 363.6
$ 341.1
$ 327.8
$ 334.8
$ 305.7
$ 274.1
$ 302.9
$ 321.5
$ 327.3
$ 287.7
$ 324.0
$ 329.6
Reported net income
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Reported income taxes
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Reported income before income taxes
$ 14.5
$ 6.1
$ 40.1
$ 24.6
$ 16.7
$ 11.0
$ 17.8
$ 22.8
$ 17.2
$ 12.6
$ 17.4
$ 21.8
Adjustments:
Restructuring initiatives
$ 1.3
$ 2.9
$ 0.6
$ 0.6
$ 0.4
$ 2.2
$ 2.0
$ 1.2
$ 2.7
$ 8.0
$ 2.9
$ 0.5
Curtailment gain related to restructuring initiatives
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Net investment (gain) loss
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Realized gain on investments included in net investment (gain) loss above
Gain from remeasurement of equity method
investment
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ - $
- $ (26.5) $ - $
- $ - $
- $ - $
- $ - $ - $ -
Transaction costs related to acquisitions Purchase accounting adjustments related to acquisitions and investments
Other special items
Adjusted earnings before income taxes Interest expense
Interest income
$ - $
$ - $
$ - $
$ 15.8 $
$ - $
$ - $
- $
0.6 $
- $
9.6 $
- $
- $
0.2 $
1.1 $
- $
15.4 $
- $
- $
0.3 $
- $
- $
25.6 $
- $
- $
- $
- $
- $
17.1 $
- $
- $
- $
- $
- $
13.2 $
- $
- $
- $
- $
- $
19.8 $
- $
- $
0.1 $
- $
- $
24.1 $
- $
- $
- $
- $
- $
19.9 $
- $
- $
0.2 $
- $
- $
20.8 $
- $
- $
- $
- $
- $
20.3 $
- $
- $
-
-
-22.3
-
-
Adjusted earnings before net interest and taxes (Adjusted $ 15.8
$ 9.6
$ 15.4
$ 25.6
$ 17.1
$ 13.2
$ 19.8
$ 24.1
$ 19.9
$ 20.8
$ 20.3
$ 22.3
Depreciation and amortization $ 24.7
$ 25.2
$ 24.3
$ 21.5
$ 20.1
$ 20.8
$ 20.4
$ 20.5
$ 21.2
$ 21.5
$ 20.8
$ 20.8
Adjusted EBITDA $ 40.5
$ 34.8
$ 39.7
$ 47.1
$ 37.1
$ 33.9
$ 40.2
$ 44.6
$ 41.1
$ 42.3
$ 41.1
$ 43.1
Adjusted EBITDA % 11.1%
10.2%
12.1%
14.1%
12.1%
12.4%
13.3%
13.9%
12.6%
14.7%
12.7%
13.1%
Aptar Closures
Net Sales $ 180.7
$ 181.6
$ 188.0
$ 188.6
$ 172.1
$ 173.3
$ 185.8
$ 174.0
$ 180.8
$ 165.7
$ 179.8
$ 175.6
Reported net income $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Reported income taxes $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Reported income before income taxes $ 9.2
$ 11.7
$ 14.7
$ 17.5
$ 12.3
$ 11.9
$ 18.0
$ 12.0
$ 12.9
$ (5.6)
$ 11.6
$ 14.2
Adjustments:
Restructuring initiatives $ 0.2
$ 0.6
$ 0.7
$ 0.9
$ 1.4
$ 1.3
$ 0.9
$ 0.9
$ 0.8
$ 13.9
$ 3.1
$ 0.4
Curtailment gain related to restructuring initiatives $ -
$ (0.1)
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Net investment (gain) loss $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Realized gain on investments included in net $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Gain from remeasurement of equity method $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Transaction costs related to acquisitions $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Purchase accounting adjustments related to $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Other special items $ -
$ -
$ -
$ -
$ -
$ -
$ (1.9)
$ -
$ -
$ -
$ -
$ -
Adjusted earnings before income taxes $ 9.4
$ 12.2
$ 15.4
$ 18.4
$ 13.7
$ 13.3
$ 17.1
$ 12.9
$ 13.6
$ 8.3
$ 14.7
$ 14.7
Interest expense $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Interest income $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Adjusted earnings before net interest and taxes (Adjusted $ 9.4
$ 12.2
$ 15.4
$ 18.4
$ 13.7
$ 13.3
$ 17.1
$ 12.9
$ 13.6
$ 8.3
$ 14.7
$ 14.7
Depreciation and amortization $ 14.2
$ 14.8
$ 14.9
$ 13.4
$ 13.6
$ 14.6
$ 14.9
$ 14.3
$ 13.5
$ 14.0
$ 12.9
$ 13.1
Adjusted EBITDA $ 23.7
$ 27.0
$ 30.3
$ 31.9
$ 27.3
$ 27.9
$ 32.0
$ 27.1
$ 27.2
$ 22.3
$ 27.6
$ 27.8
EBIT)
investment (gain) loss above investment
acquisitions and investments
EBIT)
Adjusted EBITDA % 13.1% 14.9% 16.1% 16.9% 15.8% 16.1% 17.2% 15.6% 15.0% 13.5% 15.4% 15.8%
Reconciliation of Adjusted Earnings Per Diluted
March
December
September
June
March
December
September
June
March
December
September
June
Share (Unaudited)
2026
2025
2025
2025
2025
2024
2024
2024
2024
2023
2023
2023
AptarGroup, Inc.
Income Before Income Taxes $ 93.8
$ 91.5
$ 154.1
$ 139.7
$ 106.0
$ 116.1
$ 131.1
$ 118.2
$ 104.3
$ 80.6
$ 110.0
$ 110.9
Adjustments:
Restructuring Initiatives $ 1.1
$ 4.0
$ 2.2
$ 1.6
$ 2.0
$ 3.3
$ 3.9
$ 2.3
$ 3.5
$ 25.4
$ 6.2
$ 1.9
Net Investment (Gain) / Loss $ 1.1
$ 1.3
$ 0.2
$ (2.1)
$ 1.1
$ (0.2)
$ (1.0)
$ 0.1
$ (0.6)
$ 0.4
$ 1.2
$ (2.9)
Gain from Remeasurement of Equity Method $ -
$ -
$ (26.5)
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Curtailment gain related to restructuring initiatives $ -
$ (0.1)
$ -
$ -
$ -
$ -
$ (1.9)
$ -
$ -
$ -
$ -
$ -
Realized (Gain) / Loss included in Net Investment $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ 4.2
$ -
Transaction Costs Related to Acquisitions $ 0.0
$ 0.4
$ 0.7
$ 0.3
$ -
$ -
$ -
$ 0.1
$ -
$ 0.2
$ -
$ -
Purchase Accounting Adjustments Related to $ 0.1
$ 0.6
$ 1.1
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Other Special Items $ 3.7
$ 4.0
$ 4.4
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Foreign Currency Effects $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Adjusted Earnings Before Income Taxes $ 99.9
$ 101.8
$ 136.2
$ 139.5
$ 109.2
$ 119.2
$ 132.1
$ 120.8
$ 107.2
$ 106.7
$ 121.6
$ 109.9
Provision for Income Taxes $ 21.0
$ 17.3
$ 26.3
$ 28.0
$ 27.4
$ 15.2
$ 31.2
$ 27.8
$ 21.4
$ 18.4
$ 25.8
$ 27.8
Adjustments:
Net effect of items included in the Provision for Income $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Restructuring Initiatives $ 0.3
$ 1.0
$ 0.6
$ 0.4
$ 0.5
$ 0.9
$ 1.0
$ 0.6
$ 0.9
$ 6.8
$ 1.6
$ 0.5
Net Investment (Gain) / Loss $ 0.3
$ 0.3
$ 0.0
$ (0.5)
$ 0.3
$ (0.1)
$ (0.3)
$ 0.0
$ (0.1)
$ 0.1
$ 0.3
$ (0.7)
Gain from Remeasurement of Equity Method $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Curtailment gain related to restructuring initiatives $ -
$ (0.0)
$ -
$ -
$ -
$ -
$ (0.5)
$ -
$ -
$ -
$ -
$ -
Realized (Gain) / Loss included in Net Investment $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ 1.0
$ -
Transaction Costs Related to Acquisitions $ 0.0
$ 0.1
$ 0.2
$ 0.1
$ -
$ -
$ -
$ 0.0
$ -
$ 0.1
$ -
$ -
Purchase Accounting Adjustments Related to $ 0.0
$ 0.1
$ 0.2
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Other Special Items $ 1.0
$ 1.0
$ 1.1
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Foreign Currency Effects $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Adjusted Provision for Income Taxes $ 22.6
$ 19.8
$ 28.3
$ 28.0
$ 28.1
$ 16.1
$ 31.5
$ 28.4
$ 22.1
$ 25.3
$ 28.7
$ 27.6
Net Income/Loss Attributable to Noncontrolling Interests $ (0.0)
$ 0.1
$ (0.0)
$ (0.0)
$ 0.1
$ 0.1
$ 0.1
$ (0.0)
$ 0.2
$ 0.1
$ (0.0)
$ 0.0
Net Income Attributable to Redeemable Noncontrolling $ (0.1)
$ (0.1)
$ 0.1
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Net Income Attributable to AptarGroup, Inc. $ 72.7
$ 74.3
$ 127.9
$ 111.7
$ 78.8
$ 100.9
$ 100.0
$ 90.5
$ 83.1
$ 62.4
$ 84.3
$ 83.1
Adjustments: $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Net effect of items included in the Provision for Income $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Restructuring Initiatives $ 0.8
$ 3.0
$ 1.6
$ 1.2
$ 1.5
$ 2.4
$ 2.9
$ 1.7
$ 2.6
$ 18.6
$ 4.6
$ 1.4
Net Investment (Gain) / Loss $ 0.8
$ 1.0
$ 0.1
$ (1.6)
$ 0.8
$ (0.2)
$ (0.8)
$ 0.1
$ (0.4)
$ 0.3
$ 0.9
$ (2.2)
Gain from Remeasurement of Equity Method $ -
$ -
$ (26.5)
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Curtailment gain related to restructuring initiatives $ -
$ (0.1)
$ -
$ -
$ -
$ -
$ (1.4)
$ -
$ -
$ -
$ -
$ -
Realized (Gain) / Loss included in Net Investment $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ 3.2
$ -
Transaction Costs Related to Acquisitions $ 0.0
$ 0.2
$ 0.6
$ 0.3
$ -
$ -
$ -
$ 0.1
$ -
$ 0.2
$ -
$ -
Purchase Accounting Adjustments Related to $ 0.1
$ 0.5
$ 1.0
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Other Special Items $ 2.8
$ 3.0
$ 3.3
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Foreign Currency Effects $ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
$ -
Adjusted Net Income Attributable to AptarGroup, Inc. $ 77.2
$ 82.1
$ 108.0
$ 111.5
$ 81.2
$ 103.2
$ 100.7
$ 92.4
$ 85.2
$ 81.5
$ 92.9
$ 82.3
Diluted Shares Outstanding 64,834
65,796
66,630
67,048
67,491
67,923
67,716
67,575
67,432
67,131
67,035
66,855
Adjusted EPS $ 1.19
$ 1.25
$ 1.62
$ 1.66
$ 1.20
$ 1.52
$ 1.49
$ 1.37
$ 1.26
$ 1.20
$ 1.39
$ 1.23
Investment
(Gain) / Loss above Acquisitions and Investments
Taxes
Investment
(Gain) / Loss above Acquisitions and Investments
Interests
Taxes
Investment
(Gain) / Loss above Acquisitions and Investments
Disclaimer
AptarGroup Inc. published this content on May 01, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 01, 2026 at 14:48 UTC.